The Grand Slam Bundle: Safety Profile & Research Summary
$248.06 · Free BAC water + free U.S. shipping · Same-day dispatch before 2 PM ET · FOR RESEARCH USE ONLY
Buy Grand Slam Research Kit22 PubMed CitationsExpert ReviewedLast Reviewed: July 2026
Research Summary (Component-Level)
No peer-reviewed study has evaluated this three-vial bundle as a unit. The table below lists representative findings for each component individually. Full per-component data and complete reference lists are on the dedicated GLP3-R, GLOW, and CJC (no DAC) / Ipamorelin pages.
| Component | Representative Study | Reported Observation | Ref |
|---|---|---|---|
| GLP3-R | Coskun et al. (2022) — discovery | Characterized as a triple glucagon, GIP, and GLP-1 receptor agonist | [1] |
| GLOW / GHK-Cu | Maquart et al. (1988) — fibroblast culture | Reported stimulation of collagen synthesis by the tripeptide-copper complex | [7] |
| GLOW / BPC-157 | Hsieh et al. (2017) — endothelial models | Pro-angiogenic activity associated with VEGFR2 activation | [8] |
| GLOW / TB-500 | Philp et al. (2003) — rodent dermal wounds | Actin-binding-domain peptide reported to promote dermal wound repair | [11] |
| CJC (no DAC) | Jetté et al. (2005) — rats | GRF analog reported to activate the GRF receptor on the anterior pituitary | [14] |
| Ipamorelin | Raun et al. (1998) — characterization | Described as the first selective growth hormone secretagogue | [17] |
For Laboratory Research Only. Not for human use, medical use, diagnostic use, or veterinary use.
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
In Vitro / Preclinical Disclaimer: The research findings described above were observed in laboratory (in vitro), animal model, and clinical research studies of individual compounds. Research-grade material supplied by Pure U.S. Peptides is for laboratory research use only. No claims are made regarding human therapeutic applications.
Educational Use Only: This content summarises published laboratory and clinical literature for research reference only. It is not medical advice.
Editorial Research Note
“Research Summary (Component-Level) No peer-reviewed study has evaluated this three-vial bundle as a unit.”
References
- Coskun T, Urva S, Roell WC, et al. Cell Metab. 2022;34(9):1234-1247.e9.
- Urva S, Coskun T, Loh MT, et al. Lancet. 2022;400(10366):1869-1881.
- Jastreboff AM, Kaplan LM, Frías JP, et al. N Engl J Med. 2023;389(6):514-526.
- Rosenstock J, Frias J, Jastreboff AM, et al. Lancet. 2023;402(10401):529-544.
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987.
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015;2015:648108.
- Maquart FX, Pickart L, Laurent M, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters. 1988;238(2):343-346.
- Hsieh MJ, et al. Journal of Molecular Medicine. 2017;95(3):323-333.
- Sikiric P, Hahm KB, Blagaic AB, Tvrdeic A, et al. Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future. Gut and Liver. 2020;14(2):153-167.
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Expert Opinion on Biological Therapy. 2012;12(1):37-51.
- Philp D, Badamchian M, Scheremeta B, Nguyen M, Goldstein AL, Kleinman HK. Thymosin β4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair and Regeneration. 2003;11(1):19-24.
- Lance VA, Murphy WA, Sueiras-Diaz J, Coy DH. Super-active analogs of growth hormone-releasing factor (1-29)-amide. Biochemical and Biophysical Research Communications. 1984;119(1):265-272.
- Soule S, King JA, Millar RP. The Journal of Clinical Endocrinology and Metabolism. 1994;79(4):1208-1211.
- Jetté L, et al. Endocrinology. 2005;146(7):3052-3058.
- Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Testing and Analysis. 2010;2(11-12):647-650.
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of Clinical Endocrinology & Metabolism. 2006;91(12):4792-4797.
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561.
- Gobburu JVS, Agersø H, Jusko WJ, Ynddal L. Pharmaceutical Research. 1999;16(9):1412-1416.
- Johansen PB, Nowak J, Skjaerbaek C, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research. 1999;9(2):106-113.
- Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. Journal of Pharmacology and Experimental Therapeutics. 2009;329(3):1110-1116.
- Food and Drug Administration. FDA Evaluation of CJC-1295 Related Bulk Drug Substances. FDA Briefing Document: Pharmacy Compounding Advisory Committee (PCAC) Meeting, December 4, 2024.
- World Anti-Doping Agency. The 2024 Prohibited List: International Standard. World Anti-Doping Code, 2024.
Related Research Questions
Related research
Browse all research guides in the Peptide Research Library →Want the complete research review?
Buy Grand Slam Research Kit→FOR RESEARCH USE ONLY
This content is provided for educational and informational purposes only. Products are furnished for in-vitro studies only and are not medicines, drugs, or supplements. Not approved by the FDA to prevent, treat, or cure any condition.